Okami Medical Announces First Patients Treated With The LOBO Vascular Occluder

The First Offering in the Company's Product Portfolio, LOBO-3, Recently Received 510(k) Clearance from the FDA for the Occlusion of Peripheral Arteries.

The LOBO (LOw-profile Braided Occluder) system is uniquely designed to provide interventional physicians with a single-device, one-and-done solution for the occlusion of various arterial targets without the need for multiple embolic devices.

Okami Medical advises the LOBO system combines a patented design with proprietary HDBRAIDTM technology to create a highly occlusive pore structure that substantially reduces blood flow and accelerates vessel closure.  The LOBO-3 occluder is intended for use in 1.5 to 3 mm diameter vessels.

Dr. Ripal Gandhi, Interventional Radiologist, Miami Cardiac and Vascular Institute, performed the first LOBO-3 implant.  “We have successfully utilized the LOBO-3 occluder to embolize several small vessels via a microcatheter.  The device has resulted in immediate occlusion of the target vessels.  The device tracks well and deploys precisely at the desired location.  The LOBO-3 occluder is a great addition to the embolic armamentarium for the occlusion of small vessels,” said Dr. Gandhi.

“Guided by world-class physician collaborators, Okami is committed to addressing numerous challenging aspects of peripheral vascular occlusion,” said Bob Rosenbluth, Ph.D., President, and CEO of Okami Medical.  “We are very pleased with the clinical performance of the LOBO-3 occluder in the initial cases.  The device is in clinical use at key centers and we look forward to expanding our launch in 2020.”

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.